TARSUS PHARMACEUTICALS, INC. (TARS) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $72.76M; Long-term DebtUSD $72.76M; Long-term Debt, GrossUSD $75.00M; Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $72.60M; Long-term DebtUSD $72.60M; Long-term Debt, GrossUSD $75.00M; Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $72.44M; Long-term DebtUSD $72.44M; Long-term Debt, GrossUSD $75.00M; Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $72.28M; Long-term DebtUSD $72.28M; Long-term Debt, GrossUSD $75.00M; Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
TARSUS PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium), Net USD |
|---|---|---|---|---|
| 2026-06-30 | $72.76M | $72.76M | $75.00M | (m) |
| 2026-03-31 | $72.60M | $72.60M | $75.00M | (m) |
| 2025-12-31 | $72.44M | $72.44M | $75.00M | (m) |
| 2025-09-30 | $72.28M | $72.28M | $75.00M | (m) |
| 2025-06-30 | $72.13M | $72.13M | $75.00M | (m) |
| 2025-03-31 | $71.98M | $71.98M | $75.00M | (m) |
| 2024-12-31 | $71.84M | $71.84M | $75.00M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $0.00 |
| 2024-09-30 | $71.71M | $71.71M | $75.00M | $0.00 |
| 2024-06-30 | $71.58M | $71.58M | $75.00M | $0.00 |
| 2024-03-31 | $29.93M | $29.93M | $30.00M | $-517.00K |
| 2023-12-31 | $29.82M | $29.82M | $30.00M | $-438.00K |
| 2023-09-30 | $29.71M | $29.71M | $30.00M | $-358.00K |
| 2023-06-30 | $24.61M | $24.61M | $25.00M | $-289.00K |
| 2023-03-31 | $24.52M | $24.52M | $25.00M | $-226.00K |
| 2022-12-31 | $19.43M | $19.43M | $20.00M | $-174.00K |
| 2022-09-30 | $19.36M | $19.36M | $20.00M | $-127.00K |
| 2022-06-30 | $19.26M | $19.26M | $20.00M | $-79.00K |
| 2022-03-31 | $19.18M | $19.18M | $20.00M | $-32.00K |
| 2021-12-31 | $0.00 | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |